| Literature DB >> 27758048 |
Jenny E Mullen1, John-Olof Thörngren1, Jenny J Schulze1, Magnus Ericsson1, Nina Gårevik1, Mikael Lehtihet2, Lena Ekström1.
Abstract
Today's doping tests involving longitudinal monitoring of steroid profiles are difficult in women. Women have more complex hormonal fluctuations than men and commonly take drugs such as hormonal contraceptives that are shown to affect biomarkers used in these doping tests. In this study, we followed six women's urinary steroid profile during one menstrual cycle, including both glucuronides and sulfate conjugated fractions. Additionally, we studied what happens to the steroidal module of the Athlete Biological Passport (ABP) after administration of an emergency contraceptive (levonorgestrel, NorLevo®). The study shows that there are large individual variations in all metabolites included in the ABP and that the administration of emergency contraceptives may lead to suspicious steroid profile findings in the ABP. Urinary epitestosterone concentration increased during the menstrual cycle, leading to a decrease in the testosterone/epitestosterone ratio. The ratios followed in the ABP varied widely throughout the menstrual cycle, the coefficient of variation (CV) ranging from 4 to 99%. There was a 3-fold decrease in epitestosterone 24 h post administration of the emergency contraceptive pill and androsterone, etiocholanolone, and 5β- androstan-3α,17β-diol concentrations decreased about 2-fold. When analyzed with the ABP software, one of the six women had an atypical profile after taking the emergency contraceptive. Furthermore, we could not find any alterations in excretion routes (i.e., if the metabolites are excreted as glucuronide or sulfate conjugates) during the menstrual cycle or after administration of emergency contraceptive, indicating no direct effect on phase II enzymes.Entities:
Keywords: ABP; HRMS; UHPLC; doping tests; emergency contraceptives; females; menstrual cycle; phase II metabolism; urinary steroid profile
Mesh:
Substances:
Year: 2016 PMID: 27758048 DOI: 10.1002/dta.2121
Source DB: PubMed Journal: Drug Test Anal ISSN: 1942-7603 Impact factor: 3.345